Altre lingue Aerovate Therapeutics, Inc.

Azioni

AVTE

US0080641071

Tempo reale stimato Cboe BZX Altri mercati azionari 18:15:48 12/07/2024			Variaz. 5gg	Var. 1 gen.
1,855 ^USD	-1,33%		+14,29%	-91,87%

08/07	Aerovate Therapeutics esplora alternative strategiche	CI
08/07	Aerovate Therapeutics esplorerà alternative strategiche dopo l'interruzione del trial sull'ipertensione	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Aerovate Therapeutics to Explore Strategic Alternatives	08/07
Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown	08/07
Aerovate Therapeutics to Explore Strategic Alternatives	08/07
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC	21/06
Top Midday Decliners	18/06
Sector Update: Health Care Stocks Retreat Late Afternoon	17/06
Sector Update: Health Care	17/06
Top Midday Decliners	17/06
Aerovate Therapeutics Plunges after Prospective Hypertension Medication Misses Targets in Phase 2 Study, Scraps More Testing	17/06
Aerovate scraps late-stage study of lung disorder drug	17/06
Aerovate scraps late-stage study for hypertension drug after mid-stage trial fails	17/06
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension	17/06
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2B Portion of Impahct Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension	17/06
Aerovate Therapeutics : June 2024 Corporate Presentation	01/06
Aerovate Therapeutics : May 2024 Corporate Presentation	21/05
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference	21/05
Aerovate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights	13/05
Aerovate Therapeutics : May 2024 Corporate Presentation	02/05
Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	12/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Aerovate Therapeutics, Inc.

Azioni

AVTE

US0080641071

Altre lingue

Filtri